Dianthus Therapeutics, Inc.DNTHNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank67
3Y CAGR-17.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-17.3%/yr
vs +28.9%/yr prior
Acceleration
-46.2pp
Decelerating
Percentile
P67
Within normal range
vs 3Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 75.25% |
| 2024 | 153.05% |
| 2023 | 11.78% |
| 2022 | 133.06% |
| 2021 | -74.08% |
| 2020 | -15.21% |
| 2019 | 38.76% |
| 2018 | 48.18% |
| 2017 | 382.51% |
| 2016 | 0.00% |